| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Dev. &Ops. Officer | Chief Development Officer
1 company
Shemesh Shay serves as a Chief Dev. &Ops. Officer at NVCT. Across recent SEC filings that breaks down to 18 buys and 0 sells. Those positions are worth an estimated $40.3M at current prices.
Historically, Shemesh Shay's trades have earned a strong insider score of 72/100 across 16 rated trades. Over a 12-month horizon, 68.8% of those trades were profitable, with an average 12-month return of +28.6%.
The biggest single holding is NVCT (~$40.3M) as Chief Dev. &Ops. Officer. Net of sales, the recent Form 4 record there shows accumulation of 11,399 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 12, 2022 | NVCT Nuvectis Pharma, Inc. | Chief Dev. &Ops. Officer | Buy | 1,278 | $15.85 | $20,254.66 | - | -53.2% | -10.5% | |
| Feb 7, 2022 | NVCT Nuvectis Pharma, Inc. | Chief Development Officer | Buy | 2,946 | $3.41 | $10,033.62 | +0.1% | +89.4% | +37.0% |